Succinimide Anticonvulsants Treat Expressive Language Deficit in Autism
Summary
USPTO granted patent US12599581B2 to AMS Therapeutics covering a pharmacological method for treating expressive language deficit in autistic humans using succinimide anticonvulsants (ethosuximide, methsuximide, phensuximide). The patent contains 10 claims with application number 18621580 filed on March 29, 2024.
What changed
USPTO issued patent US12599581B2 to AMS Therapeutics covering the use of succinimide anticonvulsants (ethosuximide, methsuximide, phensuximide) for treating expressive language deficit in autistic humans. The patent protects this therapeutic method with 10 claims.
For pharmaceutical companies and autism treatment developers, this patent establishes exclusive rights to this specific treatment approach. Parties developing similar therapies should assess freedom-to-operate implications. The patent's 10-claim scope provides broad protection around the method and specific compounds disclosed.
What to do next
- Monitor for potential licensing or infringement issues
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Method of treating expressive language deficit in autistic humans
Grant US12599581B2 Kind: B2 Apr 14, 2026
Assignee
AMS Therapeutics
Inventors
Charles E. Niesen
Abstract
A pharmacological method for treating the expressive language deficit in an autistic human child or adult is provided. A therapeutically effective dose of a succinimide anticonvulsant, e.g., ethosuximide, methsuximide, phensuximide, or a pharmaceutically acceptable salt thereof, is administered to a patient suffering from expressive language deficit, preferably over an extended period, e.g., six months or longer. Language gains are retained even after treatment is discontinued.
CPC Classifications
A61K 31/4015 A61P 25/08
Filing Date
2024-03-29
Application No.
18621580
Claims
10
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.